OC
CLPT icon

Oppenheimer & Co’s ClearPoint Neuro CLPT Stock Holding History

Oppenheimer & Co’s Portfolio CLPT Stock Details CLPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$272K Buy
15,250
+4,650
+44% +$58.1K ﹤0.01% 1521
2026
Q1 		$96.5K Buy
+10,600
New +$134K ﹤0.01% 1644
2024
Q4 		– Sell
-13,929
Closed -$156K – 1564
2024
Q3 		$156K Buy
+13,929
New +$133K ﹤0.01% 1431

Other funds holding CLPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LG
Lane Generational Dover, Massachusetts $114M AUM 43.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
CFM
Compass Financial Management Tampa, Florida $829M AUM

Oppenheimer & Co's CLPT Position: Q2 2026 in Review

Oppenheimer & Co increased its ClearPoint Neuro (CLPT) stake by 44% in Q2 2026, buying an estimated $58.1K and bringing the position to 15,250 shares worth $272K. The position accounts for ﹤0.01% of the portfolio, ranked #1521.

Oppenheimer & Co first reported a position in CLPT in Q3 2024 and has held it in 3 quarters since. 129 funds tracked by Wall St. Rank hold CLPT as of Q2 2026.

  • Oppenheimer & Co held 15,250 shares of ClearPoint Neuro worth $272K as of Q2 2026.
  • Oppenheimer & Co bought 4,650 ClearPoint Neuro shares in Q2 2026, an estimated $58.1K.
  • ClearPoint Neuro made up ﹤0.01% of Oppenheimer & Co's portfolio in Q2 2026, its #1521 holding.
  • Oppenheimer & Co first reported a position in ClearPoint Neuro in Q3 2024 and has held it in 3 quarters since.
  • 129 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.